
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech Inc. has demonstrated a strong positive trajectory in recent clinical studies, particularly with Ampligen, which shows potential as a treatment for multiple cancers and post-COVID conditions. Initial findings from the Phase 2 studies, including those focused on colorectal cancer and post-COVID conditions, have been promising, suggesting further positive data could act as significant catalysts for the company's stock. The company's innovative approach to addressing unmet medical needs in oncology and viral disease therapy positions AIM ImmunoTech favorably in the immuno-pharmaceutical sector.
Bears say
AIM ImmunoTech Inc. reported a net loss of $3.3 million, translating to an earnings per share (EPS) of $(1.57), which significantly missed both company and consensus estimates. The company faces substantial risks impacting its financial outlook, including balance sheet and liquidity challenges, the potential failure of key product candidates in clinical trials, and difficulties related to regulatory approvals and commercialization. Additionally, macroeconomic factors, investor sentiment toward biotech investments, and shifts in healthcare priorities pose further threats that could adversely affect AIM ImmunoTech's stock performance.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares